Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC-ND 4.0Future Oncology

Durvalumab plus etoposide–carboplatin for advanced digestive neuroendocrine carcinoma: a phase III trial (JCOG2107E)

9 more authors
16 affiliations
  1. 1Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan
  2. 2Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan
  3. 3Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
  4. 4Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
  5. 5Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
  6. 6Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan
  7. 7Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan
  8. 8Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan
  9. 9Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan
  10. 10Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  11. 11Department of Cancer Center, Hokkaido University Hospital, Sapporo, Japan
  12. 12Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan
  13. 13Third Department of Internal Medicine, University of Toyama, Toyama, Japan
  14. 14Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya, Japan
  15. 15Department of Gastroenterology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
  16. 16Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Abstract

Digestive neuroendocrine carcinoma (NEC) is a rare and highly aggressive malignancy, with an annual incidence of approximately 0.4–0.8 per 100,000 population. Due to its biological similarities with small cell lung cancer (SCLC), regimens such as etoposide plus cisplatin, irinotecan plus cisplatin, and etoposide plus carboplatin (EC) have been adopted as the standard treatments in unresectable or recurrent digestive NEC. However, its prognosis remains poor, thus requiring new treatment strategies. Immune checkpoint inhibitors plus cytotoxic chemotherapy have shown promise in the treatment of extensive-stage SCLC, warranting further exploration of their potential role in digestive NEC. An open-label randomized phase III investigator-initiated trial has been conducted since November 2023 to confirm the superiority of adding durvalumab to EC in chemotherapy-naive patients with unresectable or recurrent digestive NEC. A total of 74 patients will be enrolled from 14 institutions over 3 years. The primary endpoint is overall survival, while the secondary endpoints are progression-free survival, objective response rate, and incidence of adverse events.

Clinical trial registration: jRCT2031230456 (https://jrct.mhlw.go.jp/latest-detail/jRCT2031230456).

Related

  1. Comparative Evaluation of Concurrent Carboplatin-Paclitaxel Versus Cisplatin-Etoposide Chemoradiotherapy in Unresectable Non-small Cell Lung Cancer: A Prospective Randomized Study
    Yamini Kumar, Bala Venkat Subramanian, G V Deepthi +2
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Berberine and Etoposide Exert Synergistic Anticancer Effects in A431 Epidermoid Carcinoma Cells
    Zeynep Özlem Cinar, Valerija Šatrova, Akshay Kumar Vijaya +4
    ACS omegaPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMCCrossref
  3. Genetic intratumour heterogeneity in digestive high-grade neuroendocrine neoplasms.
    Siren Morken, Halfdan Sorbye, Wei Deng +12
    Journal of neuroendocrinologyPeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthEurope PMC
  4. A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment
    Saki Sueda, Tomokazu Kawaoka, Yasutoshi Fujii +7
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  5. Favorable Response to Chemotherapy with Durvalumab Plus Tremelimumab in Two Cases of KRAS G12C-positive Pulmonary Sarcomatoid Carcinoma
    Takeru Ichikawa, Kenichiro Kudo, Yuki Takigawa +7
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
BibTeX
@article{sano2026durvalumab,
  title = {{Durvalumab plus etoposide–carboplatin for advanced digestive neuroendocrine carcinoma: a phase III trial (JCOG2107E)}},
  author = {Yusuke Sano and Yuta Maruki and Chigusa Morizane and Shogo Nomura and Haruhiko Fukuda and Masafumi Ikeda and Masato Ozaka and Satoshi Kobayashi and Kazuyoshi Ohkawa and Nobumasa Mizuno and Hidetaka Tsumura and Nao Fujimori and Yoshito Komatsu and Noboru Takata and Ichiro Yasuda and Kohei Nakachi and Toru Otsuru and Takuya Honda and Takuji Okusaka and Makoto Ueno and on behalf of the Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group},
  journal = {Future Oncology},
  year = {2026},
  month = oct,
  doi = {10.1080/14796694.2026.2749305},
  url = {https://doi.org/10.1080/14796694.2026.2749305},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Durvalumab plus etoposide–carboplatin for advanced digestive neuroendocrine carcinoma: a phase III trial (JCOG2107E)
AU  - Yusuke Sano
AU  - Yuta Maruki
AU  - Chigusa Morizane
AU  - Shogo Nomura
AU  - Haruhiko Fukuda
AU  - Masafumi Ikeda
AU  - Masato Ozaka
AU  - Satoshi Kobayashi
AU  - Kazuyoshi Ohkawa
AU  - Nobumasa Mizuno
AU  - Hidetaka Tsumura
AU  - Nao Fujimori
AU  - Yoshito Komatsu
AU  - Noboru Takata
AU  - Ichiro Yasuda
AU  - Kohei Nakachi
AU  - Toru Otsuru
AU  - Takuya Honda
AU  - Takuji Okusaka
AU  - Makoto Ueno
AU  - on behalf of the Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group
PY  - 2026
DA  - 2026/10/22
JO  - Future Oncology
DO  - 10.1080/14796694.2026.2749305
UR  - https://doi.org/10.1080/14796694.2026.2749305
AB  - Digestive neuroendocrine carcinoma (NEC) is a rare and highly aggressive malignancy, with an annual incidence of approximately 0.4–0.8 per 100,000 population. Due to its biological similarities with small cell lung cancer (SCLC), regimens such as etoposide plus cisplatin, irinotecan plus cisplatin, and etoposide plus carboplatin (EC) have been adopted as the standard treatments in unresectable or recurrent digestive NEC. However, its prognosis remains poor, thus requiring new treatment strategies. Immune checkpoint inhibitors plus cytotoxic chemotherapy have shown promise in the treatment of extensive-stage SCLC, warranting further exploration of their potential role in digestive NEC. An open-label randomized phase III investigator-initiated trial has been conducted since November 2023 to confirm the superiority of adding durvalumab to EC in chemotherapy-naive patients with unresectable or recurrent digestive NEC. A total of 74 patients will be enrolled from 14 institutions over 3 years. The primary endpoint is overall survival, while the secondary endpoints are progression-free survival, objective response rate, and incidence of adverse events.  Clinical trial registration: jRCT2031230456 (https://jrct.mhlw.go.jp/latest-detail/jRCT2031230456).
SN  - 1479-6694
SN  - 1744-8301
ER  -